Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 16/20 | 0.54 |
| ▸ | KDR | P35968 | 5/20 | 0.54 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | SCD | O00767 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2193478 | 0.91 | BRAF (0.53) | BRAFKDRCYP2C9 | |
| SCHEMBL2194047 | 0.89 | BRAF (0.57) | BRAFKDRRAB9AMAPTSCD | |
| SCHEMBL2195229 | 0.87 | BRAF (0.59) | BRAFKDRRAB9AMAPTPOLB | |
| SCHEMBL2194840 | 0.87 | BRAF (0.71) | BRAFKDRSCD | |
| SCHEMBL2854386 | 0.86 | BRAF (0.51) | BRAFKDRCYP2C9 | |
| SCHEMBL2195132 | 0.84 | BRAF (0.54) | BRAFKDRPOLBCYP2C9 | |
| SCHEMBL2192601 | 0.84 | BRAF (0.53) | BRAFKDRRAB9AMAPTPOLB | |
| SCHEMBL2193226 | 0.83 | RAB9A (0.47) | BRAFKDRRAB9AMAPTPOLB | |
| SCHEMBL2192213 | 0.82 | BRAF (0.47) | BRAFKDRSCDALDH1A1CYP2C9 | |
| SCHEMBL2191163 | 0.82 | ALDH1A1 (0.56) | BRAFKDRPOLBSCDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2181987-B9 | 2-Carbonylaminobenzothiazoles and their use for the prophylaxis and treatment of cancer | TAKEDA PHARMACEUTICAL (JP) | 2014-09-03 | — | — | EP | disclosed |
| EP-2181987-B1 | 2-Carbonylaminobenzothiazoles and their use for the prophylaxis and treatment of cancer | TAKEDA PHARMACEUTICAL (JP) | 2014-03-05 | — | — | EP | disclosed |
| US-8324395-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-12-04 | — | — | US | disclosed |
| US-20110172245-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-07-14 | — | — | US | disclosed |
| EP-2181987-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2010-05-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172245-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | BRAF, NRAS, RAF1 | BRAF 1/4885KDR 843/4885RAB9A 382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.